Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) concerning whether a series of statements by Sunesis Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 23, 2015, Sunesis Pharmaceuticals disclosed that the Food and Drug Administration turned down the filing of a New Drug Application for its proposed leukemia treatment, vosaroxin, because it fell short of the desired statistical significance on the protocol-defined primary analysis of overall survival. On this news, shares of Sunesis Pharmaceuticals fell $2.51 per share or over 70% on July 24, 2015, damaging investors.

Based in South San Francisco, CA and founded in 1998, Sunesis Pharmaceuticals Inc is a biopharmaceutical company that develops and markets oncology therapeutics for the treatment of solid and hematologic cancers. The flagship drug it is developing is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML).

If you purchased shares of Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) on or before July 23, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185